



## NOTICE OF TEXT

### [Authority G.S. 150B-21.2(c)]

**OAH USE ONLY**

VOLUME: 40

ISSUE: 17

CHECK APPROPRIATE BOX:

- Notice with a scheduled hearing
- Notice without a scheduled hearing
- Republication of text. Complete the following cite for the volume and issue of previous publication, as well as blocks 1 - 4 and 7 - 14. If a hearing is scheduled, complete block 5.  
Previous publication of text was published in Volume: Issue:

1. Rule-Making Agency: [Medical Board and Board of Pharmacy](#)

---

2. Link to agency website pursuant to G.S. 150B-19.1(c): <https://www.ncmedboard.org/about-the-board/latest-board-activity/rule-change-tracker>

---

3. Proposed Action -- Check the appropriate box(es) and list rule citation(s) beside proposed action:

ADOPTION: 21 NCAC 32U .0103

AMENDMENT:

REPEAL:

READOPTION with substantive changes:

READOPTION without substantive changes:

REPEAL through READOPTION:

---

4. Proposed effective date: 08/01/2026

---

5. Is a public hearing planned? **Yes**

If yes:

Date	Time	Location
03/17/2026	9:00 A.M.	North Carolina Board of Pharmacy, 6015 Farrington Road, Suite 201, Chapel Hill, NC 27517

---

6. If no public hearing is scheduled, provide instructions on how to demand a public hearing:

**7. Explain Reason For Proposed Rule(s):**

Last year, the Legislature enacted SL 2025-37. This new law authorizes pharmacists to test for and initiate treatment for influenza. In September 2025, the State Health Director issued two standing orders implementing the new law. The Medical Board and Board of Pharmacy propose rules that adopt the standing orders of the State Health Directors as protocol.

**8. Procedure for Subjecting a Proposed Rule to Legislative Review:** If an objection is not resolved prior to the adoption of the rule, a person may also submit written objections to the Rules Review Commission. If the Rules Review Commission receives written and signed objections in accordance with G.S. 150B-21.3(b2) from 10 or more persons clearly requesting review by the legislature and the Rules Review Commission approves the rule, the rule will become effective as provided in G.S. 150B-21.3(b1). The Commission will receive written objections until 5:00 p.m. on the day following the day the Commission approves the rule. The Commission will receive those objections by mail, delivery service, hand delivery, or email. If you have any further questions concerning the submission of objections to the Commission, please call a Commission staff attorney at 984-236-1850.

**Rule(s) is automatically subject to legislative review. Cite statutory reference:**

**9. The person to whom written comments may be submitted on the proposed rule(s):**

Name: Leigh Anne Satterwhite  
Address: 3127 Smoketree Court  
Raleigh, NC 27604  
Phone (optional): 919-326-1109, Ext. 395  
Fax (optional):  
EMail (optional) rules@ncmedboard.org

**10. Comment Period Ends: 05/01/2026**

**11. Fiscal impact. Does any rule or combination of rules in this notice create an economic impact? Check all that apply.**

No fiscal note required

**12. Rule-making Coordinator:**

Name: Leigh Anne Satterwhite  
919-326-1109 Ext. 395  
leigh.satterwhite@ncmedboard.org

**Agency contact, if any:**

Name: Marcus Jimison  
Phone: 919-326-1109, Ext. 226  
Email: marcus.jimison@ncmedboard.org

**13. The Agency formally proposed the text of this rule(s) on**

**Date:** 01/23/2026

1 21 NCAC 32. 0103 is proposed for adoption as follows:  
2

3 **SUBCHAPTER 32U - PHARMACISTS VACCINATIONS AND ADMINISTRATION OF LONG-ACTING**  
4 **INJECTABLES**

5  
6 **SECTION .0100 - PHARMACISTS VACCINATIONS AND ADMINISTRATION OF LONG-ACTING**  
7 **INJECTABLES**

8  
9 **21 NCAC 32U .0103 INFLUENZA TEST AND TREAT**

10 Pharmacists may, in accordance with 21 NCAC 46 .2517, initiate CLIA-waived testing and treatment for influenza,  
11 including prophylactic treatment for certain high-risk patients who have been exposed to influenza.

12  
13 *History Note: Authority S.L. 2025-37, s. 5.3*

14 *Eff. August 1, 2026*